Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data

Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 91; no. 2; p. 227
Main Authors Bauer, M, Zeitlinger, M, Karch, R, Matzneller, P, Stanek, J, Jäger, W, Böhmdorfer, M, Wadsak, W, Mitterhauser, M, Bankstahl, J P, Löscher, W, Koepp, M, Kuntner, C, Müller, M, Langer, Oliver
Format Journal Article
LanguageEnglish
Published United States 01.02.2012
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects. We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology. Tariquidar was equipotent in humans and rats in its effect of increasing (R)-[(11)C]verapamil brain uptake (expressed as whole-brain volume of distribution (V(T))), with very similar half-maximum-effect concentrations. Both in humans and in rats, brain V(T) approached plateau levels at plasma tariquidar concentrations >1,000 ng/ml. However, Pgp inhibition in humans led to only a 2.7-fold increase in brain V(T) relative to baseline scans (before administration of tariquidar) as compared with 11.0-fold in rats. The results of this translational study add to the accumulating evidence that there are marked species-dependent differences in Pgp expression and functionality at the BBB.
AbstractList Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp) substrate) and escalating doses of the Pgp inhibitor tariquidar (3, 4, 6, and 8 mg/kg) at the blood-brain barrier (BBB) in healthy human subjects. We compared the dose-response relationship of tariquidar in humans with data obtained in rats using a similar methodology. Tariquidar was equipotent in humans and rats in its effect of increasing (R)-[(11)C]verapamil brain uptake (expressed as whole-brain volume of distribution (V(T))), with very similar half-maximum-effect concentrations. Both in humans and in rats, brain V(T) approached plateau levels at plasma tariquidar concentrations >1,000 ng/ml. However, Pgp inhibition in humans led to only a 2.7-fold increase in brain V(T) relative to baseline scans (before administration of tariquidar) as compared with 11.0-fold in rats. The results of this translational study add to the accumulating evidence that there are marked species-dependent differences in Pgp expression and functionality at the BBB.
Author Bauer, M
Jäger, W
Stanek, J
Wadsak, W
Zeitlinger, M
Mitterhauser, M
Müller, M
Langer, Oliver
Kuntner, C
Böhmdorfer, M
Löscher, W
Matzneller, P
Koepp, M
Karch, R
Bankstahl, J P
Author_xml – sequence: 1
  givenname: M
  surname: Bauer
  fullname: Bauer, M
  organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
– sequence: 2
  givenname: M
  surname: Zeitlinger
  fullname: Zeitlinger, M
– sequence: 3
  givenname: R
  surname: Karch
  fullname: Karch, R
– sequence: 4
  givenname: P
  surname: Matzneller
  fullname: Matzneller, P
– sequence: 5
  givenname: J
  surname: Stanek
  fullname: Stanek, J
– sequence: 6
  givenname: W
  surname: Jäger
  fullname: Jäger, W
– sequence: 7
  givenname: M
  surname: Böhmdorfer
  fullname: Böhmdorfer, M
– sequence: 8
  givenname: W
  surname: Wadsak
  fullname: Wadsak, W
– sequence: 9
  givenname: M
  surname: Mitterhauser
  fullname: Mitterhauser, M
– sequence: 10
  givenname: J P
  surname: Bankstahl
  fullname: Bankstahl, J P
– sequence: 11
  givenname: W
  surname: Löscher
  fullname: Löscher, W
– sequence: 12
  givenname: M
  surname: Koepp
  fullname: Koepp, M
– sequence: 13
  givenname: C
  surname: Kuntner
  fullname: Kuntner, C
– sequence: 14
  givenname: M
  surname: Müller
  fullname: Müller, M
– sequence: 15
  givenname: Oliver
  surname: Langer
  fullname: Langer, Oliver
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22166851$$D View this record in MEDLINE/PubMed
BookMark eNo1kEtLAzEUhYMo1laXbiVLXUzNTSaZGXdSfEFBEV2JlJvH2Mi8zKQWV_51A-rqXDh8h3vOlOx2fecIOQY2BybKc9MMcc4ZwJxDsUMOQAqeKSnkhEzH8Z0xlldluU8mnINSpYQD8v3wNmStsx6js9R30QU00fcd1S5unevo6eNZ9gKweP1M1oCtbyh2lkYM_mPjLQaKkca1o-tNiwlr-t5mOqBPN4bgXbigSE3fDokYU_DWxzUNCbIY8ZDs1diM7uhPZ-T5-uppcZst72_uFpfLzIi8KDJZo1Tpf6tAmQo11twKk1c6FSkAlagq6TTUlQNuSmQgZM6YqhmrgBkt-Iyc_OYOG53qrobgWwxfq_8l-A_LGGBa
CitedBy_id crossref_primary_10_1159_000343243
crossref_primary_10_3390_pharmaceutics12100966
crossref_primary_10_1002_jcph_722
crossref_primary_10_1124_dmd_114_058685
crossref_primary_10_1186_s10194_024_01894_0
crossref_primary_10_2174_1872312815666220222091032
crossref_primary_10_1016_j_ejphar_2012_09_013
crossref_primary_10_1016_j_jointm_2023_01_001
crossref_primary_10_1007_s00232_015_9804_y
crossref_primary_10_1111_cts_13804
crossref_primary_10_1016_j_brainresbull_2022_09_017
crossref_primary_10_1038_aps_2015_64
crossref_primary_10_1038_jcbfm_2015_19
crossref_primary_10_1021_jacs_2c03944
crossref_primary_10_1021_cn3001729
crossref_primary_10_1124_dmd_112_049577
crossref_primary_10_2967_jnumed_112_111732
crossref_primary_10_1093_brain_aws147
crossref_primary_10_2967_jnumed_112_118232
crossref_primary_10_1007_s11307_023_01864_z
crossref_primary_10_1038_clpt_2013_34
crossref_primary_10_1093_ijnp_pyu078
crossref_primary_10_1038_jcbfm_2012_112
crossref_primary_10_1002_cpt_73
crossref_primary_10_1146_annurev_pharmtox_010617_052438
crossref_primary_10_1186_2191_219X_2_58
crossref_primary_10_1177_0271678X211045444
crossref_primary_10_3389_fonc_2020_561936
crossref_primary_10_1016_j_xphs_2023_10_034
crossref_primary_10_1016_j_pharmthera_2018_04_006
crossref_primary_10_1021_acs_molpharmaceut_3c01036
crossref_primary_10_1038_s41573_020_0080_x
crossref_primary_10_2174_1872312813666190311125652
crossref_primary_10_1021_mp5008103
crossref_primary_10_1016_j_clgc_2019_05_016
crossref_primary_10_1212_WNL_0000000000000858
crossref_primary_10_1016_j_ejps_2019_105122
crossref_primary_10_1016_j_therap_2020_02_018
crossref_primary_10_1002_cmdc_201500420
crossref_primary_10_1016_j_nucmedbio_2015_09_003
crossref_primary_10_1177_0271678X231202336
crossref_primary_10_1002_jlcr_2993
crossref_primary_10_1021_jm301297f
crossref_primary_10_1517_17425255_2013_741589
crossref_primary_10_1073_pnas_1312159110
crossref_primary_10_1016_j_nbd_2014_04_001
crossref_primary_10_1007_s00204_021_03115_y
crossref_primary_10_1007_s13318_024_00908_1
crossref_primary_10_1016_j_zemedi_2014_02_003
crossref_primary_10_1016_j_tiv_2017_07_015
crossref_primary_10_1002_cpt_362
crossref_primary_10_1007_s11307_015_0883_z
crossref_primary_10_1080_20502877_2019_1564003
crossref_primary_10_1124_dmd_114_059873
crossref_primary_10_1002_cbic_201300770
crossref_primary_10_1186_s12987_020_00202_7
crossref_primary_10_1186_s12987_024_00562_4
crossref_primary_10_1007_s13318_018_0474_x
crossref_primary_10_1016_j_seizure_2024_05_007
crossref_primary_10_1016_j_ddtec_2014_03_014
crossref_primary_10_2967_jnumed_114_146894
crossref_primary_10_1016_j_xphs_2017_03_024
crossref_primary_10_3389_fphar_2021_698966
crossref_primary_10_1002_prp2_151
crossref_primary_10_1038_clpt_2014_70
crossref_primary_10_1016_j_ejps_2023_106404
crossref_primary_10_1016_S1474_4422_13_70109_1
crossref_primary_10_1208_s12248_015_9752_6
crossref_primary_10_1016_j_bmc_2016_05_039
crossref_primary_10_1016_j_ddtec_2014_03_008
crossref_primary_10_1021_acs_molpharmaceut_5b00168
crossref_primary_10_1016_j_drup_2015_02_002
crossref_primary_10_1016_j_neuroscience_2014_07_030
crossref_primary_10_1080_17425247_2016_1227786
crossref_primary_10_1124_dmd_115_065946
crossref_primary_10_2967_jnumed_115_158055
crossref_primary_10_1111_bcp_13301
crossref_primary_10_1016_j_heliyon_2022_e09777
crossref_primary_10_1097_WCO_0000000000000072
crossref_primary_10_3389_fnins_2017_00396
crossref_primary_10_1097_RLI_0b013e3182a70043
crossref_primary_10_1007_s10928_024_09957_0
crossref_primary_10_1097_ALN_0000000000000391
crossref_primary_10_1177_0271678X20965500
crossref_primary_10_1002_smll_202003309
crossref_primary_10_1128_AAC_00486_13
crossref_primary_10_1021_mp300472y
crossref_primary_10_1016_j_brainres_2014_08_060
crossref_primary_10_1007_s00508_015_0778_7
crossref_primary_10_1016_j_biomaterials_2018_10_023
crossref_primary_10_1016_j_nucmedbio_2013_05_005
crossref_primary_10_1016_j_ejca_2013_01_001
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1038/clpt.2011.217
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1532-6535
ExternalDocumentID 22166851
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GrantInformation_xml – fundername: Austrian Science Fund FWF
  grantid: F 3513
GroupedDBID ---
--K
-Q-
.55
.GJ
0R~
1B1
1CY
1OB
1OC
29B
33P
354
36B
39C
3O-
4.4
52O
53G
5GY
5RE
6J9
70F
8F7
AAESR
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQOH
AAQQT
AAWTL
AAYCA
AAYOK
AAZKR
ABCUV
ABJNI
ABLJU
ABQWH
ACBNA
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACPOU
ACRPL
ACXQS
ACYXJ
ADBBV
ADBTR
ADKYN
ADNMO
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AENEX
AEQDE
AEUYR
AEYWJ
AFBPY
AFFNX
AFFPM
AGHNM
AGQPQ
AGYGG
AHBTC
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMYDB
ASPBG
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BMXJE
BRXPI
C45
CAG
CGR
COF
CS3
CUY
CVF
DCZOG
DPXWK
DU5
EBS
ECM
EE.
EIF
EJD
EMOBN
F5P
GODZA
GWYGA
HGLYW
IH2
IHE
J5H
L7B
LATKE
LEEKS
LITHE
LOXES
LSO
LUTES
LYRES
M41
MEWTI
N4W
N9A
NPM
NQ-
O9-
OPC
OVD
P2P
P2W
PALCI
RIG
RIWAO
RJQFR
RNTTT
ROL
RPZ
SAMSI
SEW
SJN
SUPJJ
TEORI
TWZ
UHS
VH1
WBKPD
WH7
WOHZO
WXSBR
X7M
Y6R
YFH
YOC
YXB
ZGI
ZXP
ZZTAW
ID FETCH-LOGICAL-c3477-5fa56000d616c9abaf2d3c49b21671a63995eb1f9e12c8a01354006f00910cb32
IngestDate Sat May 31 02:07:31 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3477-5fa56000d616c9abaf2d3c49b21671a63995eb1f9e12c8a01354006f00910cb32
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/3685270
PMID 22166851
ParticipantIDs pubmed_primary_22166851
PublicationCentury 2000
PublicationDate February 2012
PublicationDateYYYYMMDD 2012-02-01
PublicationDate_xml – month: 02
  year: 2012
  text: February 2012
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical pharmacology and therapeutics
PublicationTitleAlternate Clin Pharmacol Ther
PublicationYear 2012
SSID ssj0004988
Score 2.380036
Snippet Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction between a microdose of (R)-[(11)C]verapamil (a P-glycoprotein (Pgp)...
SourceID pubmed
SourceType Index Database
StartPage 227
SubjectTerms Animals
ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors
Blood-Brain Barrier - diagnostic imaging
Blood-Brain Barrier - drug effects
Brain - diagnostic imaging
Brain - metabolism
Calcium Channel Blockers - pharmacology
Carbon Radioisotopes
Dose-Response Relationship, Drug
Humans
Positron-Emission Tomography - methods
Positron-Emission Tomography - statistics & numerical data
Quinolines - blood
Quinolines - pharmacology
Rats
Species Specificity
Verapamil - pharmacokinetics
Title Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data
URI https://www.ncbi.nlm.nih.gov/pubmed/22166851
Volume 91
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9RAEF6u9sUX0dbfWubBFqVdzSbZvaRvWpWiKIdcoShSdvc2paBnPHJC--If5D_ZmezuJVd_oL6EsJsLYb-PuZlh5hvGHhSqUsKWgg_xv4Zj_KW50WgMk1w7rawRtg0U37xV-wf5q0N5OBj86FUtzRvz2J79sq_kf1DFNcSVumT_AdnFS3EB7xFfvCLCeP0rjEfHNW9bP8htJOGHWZj8HauvKD-AsT7flM-E2NuUz79RtxXlNHzlJAbKX-cnEz0LPY1hZJ-vZjc0PWLb6BkNtfNN0babWtgmcJE-26G7rdM7iL2WdaeKfRoLNWOvV5ec13NPmkUG6L3D17TJxqXl1zpMrerqhHVzRkU6_sFRP39BhSCLWhAXbW7KlfSqJdEo-xFegXxp38J6KYGfLL_Xebef6sbrsqZi6Tk8pfpzS4M0FUoVXuX2z7sXhLjj1gpbwZCEZqxSYii24JZFESRc8UueLH0HCU6H314IXlonZnyVXQnRBzz1VLrGBm66xrZGHqjTHRj3ENqBLRj1IFxn3_t8gx7fIPANHr57xD8g0z4ueAYIPHQ8A90A0gBankGPZxB4tgsaOpYBsQyQZUAsu84OXr4Y7-3zMMCD2ywfDrmsNDnUyUQJZUttdJVOMpuXBk9jKDQ5xxJ9hap0IrWFxmgE44dEVQk5sdZk6Q12afpl6m4xkFLqpDAuy22el1QzjaG-zZwpCoc-rrvNbvqDPaq9SstRPPI7v925yy53hLzHVis0C-4--piN2WjRPQcL6n0p
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pgp-mediated+interaction+between+%28R%29-%5B11C%5Dverapamil+and+tariquidar+at+the+human+blood-brain+barrier%3A+a+comparison+with+rat+data&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Bauer%2C+M&rft.au=Zeitlinger%2C+M&rft.au=Karch%2C+R&rft.au=Matzneller%2C+P&rft.date=2012-02-01&rft.eissn=1532-6535&rft.volume=91&rft.issue=2&rft.spage=227&rft_id=info:doi/10.1038%2Fclpt.2011.217&rft_id=info%3Apmid%2F22166851&rft_id=info%3Apmid%2F22166851&rft.externalDocID=22166851